Research and Markets: The Global Acute Ischemic Stroke (AIS) Market Is Forecast To Grow At A (CAGR) Of 3.4% for the Next Seven Years to Reach $3.6 Billion By 2015

DUBLIN--(BUSINESS WIRE)--Research and Markets(http://www.researchandmarkets.com/research/8a4ac9/acute_ischemic_str) has announced the addition of GlobalData's new report "Acute Ischemic Stroke - Drug Pipeline Analysis and Market Forecasts to 2015" to their offering.

“Acute Ischemic Stroke - Drug Pipeline Analysis and Market Forecasts to 2015”

Executive Summary:

"Acute Ischemic Stroke - Drug Pipeline Analysis and Market Forecasts to 2015" is an essential source of information and analysis on the global Acute Ischemic Stroke (AIS) market. The report identifies the key trends shaping and driving the global AIS market. The report also provides insight on the prevalent competitive landscape and the emerging players. Most importantly, the report provides valuable insight on the pipeline products within the global AIS sector.

The Acute Ischemic Stroke Therapeutics Market is Forecast to Show Low Growth till 2015

The authors estimated the global Acute Ischemic Stroke (AIS) market to be valued at $2.9 billion in 2008. It is forecast to grow at a Compound Annual Growth Rate (CAGR) of 3.4% for the next seven years to reach $3.6 billion by 2015. This is primarily attributed to a weak pipeline landscape. Due to the fact that the weak pipeline, the delay in seeking treatment within the three hour therapeutic window, and the clinical trial failure rate continue to pose significant challenges for prospective market entrants, the market landscape in the future is expected to remain static. The ageing population will be a key driver of this market.

A Weak Market with Only One Approved Product for Treating the Acute Phase of the Disease

The authors analyzed the current market landscape and found it to be weak. There is only one approved product and an older generic, aspirin, serving the entire acute phase of the AIS market. Recombinant tissue Plasminogen Activator (rt-PA) treats the acute phase of ischemic stroke and occupies the major market share for the acute phase. However, generics also occupy a considerable market share as the majority of the patient pool is ineligible to receive this treatment. The competitive landscape of the acute phase of the ischemic stroke market is populated by a single product and by some generics for maintenance. The weak point in this landscape is that the only marketed product available has low efficacy and safety. Patient satisfaction remains low and physician satisfaction, in terms of rt-PA, is high only within the three-hour therapeutic window. New entrants into the market will be forced to match or exceed both the efficacy and safety profile of the current marketed product.

A Lucrative Market with High Unmet Need

The report finds that the global AIS market is a highly lucrative market with high unmet needs. The fact that the product currently on the market does not serve the unmet need of a larger therapeutic window, better efficacy and safety, and being suitable for a wider patient pool, results in the market continuing to present opportunities for stronger pipeline candidates. This historically static market offers huge potential for any drug maker whose drug can meet the unmet needs of the market. At the same time, this market is continuously haunted by high clinical trial failure making it a market with high commercial risk. The clinical trial failure is mainly due to poor clinical trial design, certain methodological defects, and high animal model unpredictability. This is a market with huge potential for opportunity for which technologically innovative products will be required for value capture. However, if a company wants to capture this unmet need, it will need to overcome prevailing product weaknesses and major adverse effects such as Intracranial Hemorrhage (ICH). Currently, these are the biggest challenges preventing most pipeline products from capturing the unmet need of this market

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by a team of industry experts.

Scope

The scope of the report includes:

Annualized global AIS market revenues data from 2000 to 2008, forecast forward for 7 years to 2015.
Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. The pipeline candidates fall under the major categories like thrombolytics, neuroprotectants, anticoagulants, antiplatelets.
Analysis of the current and future market competition in the global AIS market. Key future market players covered are Lundbeck, ThromboGenics and Vernalis holding the molecules that can directly treat the acute phase of the disease in the pipeline. Apart from these companies, Bayer, Bristol-Myers Squibb and Boehringer Ingelheim are found to be the companies with noticeable Phase III molecules for conditions like stroke prevention in atrial fibrillation.
Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with AIS.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global AIS market.
Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global AIS market in future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
What's the next big thing in the global AIS market landscape? - Identify, understand and capitalize.

Key Topics Covered:

1 Overview
2 Acute Ischemic Stroke Market: Market Characterization
3 Acute Ischemic Stroke Market: Competitive Assessment
4 Acute Ischemic Stroke Market: Pipeline Assessment
5 Acute Ischemic Stroke Market: Implications for Future Market Competition
6 Acute Ischemic Stroke Market: Future Players in the Acute Ischemic Stroke Market
7 Acute Ischemic Stroke Market: Appendix
List of Tables
List of Figures

Companies Mentioned: